Accelerated reversal of carbon tetrachloride-induced cirrhosis in rats by the endothelin receptor antagonist TAK-044

被引:14
|
作者
Anselmi, K
Subbotin, VM
Nemoto, E
Gandhi, CR
机构
[1] Univ Pittsburgh, Thomas E Starzl Transplantat Inst, Dept Surg, Pittsburgh, PA 15213 USA
[2] Univ Pittsburgh, Vet Adm Med Ctr, Dept Neurosurg, Pittsburgh, PA 15213 USA
[3] Univ Pittsburgh, Vet Adm Med Ctr, Dept Pathol, Pittsburgh, PA 15213 USA
关键词
antagonist; cirrhosis; endothelin; fibrosis; liver; receptor;
D O I
10.1046/j.1440-1746.2002.02705.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: A multifunctional mediator, endothelin (ET)-1 is implicated in the pathophysiology of liver cirrhosis. Carbon tetrachloride (CCl4)-induced cirrhosis in rats resolves upon termination of CCl4 treatment. We determined the hepatic ET-1 system during such reversal and assessed whether ET-1 receptor antagonism enhances this process. Methods: Cirrhosis was induced in rats by CCl4 treatment for 8 weeks. Treatment with an ETA/ETB antagonist TAK-044 (10 mg/kg per day) was then started and determinations were made at 1, 2 and 4 weeks. Results: After termination of CCl4 treatment, accelerated normalization of liver architecture and portal hypertension occurred in TAK-044-treated rats compared with saline-treated rats. The increased hepatic hydroxyproline concentration and collagen I mRNA expression also declined to greater extents in the TAK-044-treated group. Higher collagenase activity in cirrhosis decreased in saline-treated rats, but did not reach basal values. In TAK-044-treated rats, collagenase activity tended to increase at weeks 2 and 4. Increased ET-1 concentration and ETA receptor density declined to normal values in both groups. In contrast, increased ETB receptor density did not change in saline-treated rats, but decreased to control values in TAK-044-treated rats. Conclulsions: Our results emphasize the role of ET-1 in chronic liver disease and strongly indicate the potential for ET-1 receptor antagonists in its treatment. (C) 2002 Blackwell Publishing Asia Pty Ltd.
引用
收藏
页码:589 / 597
页数:9
相关论文
共 50 条
  • [1] Enhancement of the reversal of carbon tetrachloride-induced liver cirrhosis in rats by endothelin receptor antagonist TAK-044
    Anselmi, K
    Nemoto, E
    Subbotin, V
    Uemura, T
    Gandhi, CR
    FASEB JOURNAL, 2001, 15 (05): : A944 - A944
  • [2] Endothelin receptor antagonist TAK-044 arrests and reverses the development of carbon tetrachloride induced cirrhosis in rats
    Thirunavukkarasu, C
    Yang, Y
    Subbotin, VM
    Harvey, SAK
    Fung, J
    Gandhi, CR
    GUT, 2004, 53 (07) : 1010 - 1019
  • [3] Beneficial effects of endothelin receptor antagonist TAK-044 on the development of fibrosis/cirrhosis induced by carbon tetrachloride in rats
    Chinnasamy, T
    Yang, YP
    Subbotin, VM
    Fung, J
    Gandhi, CR
    FASEB JOURNAL, 2004, 18 (05): : A939 - A939
  • [4] Accelerated reversal of cirrhosis in carbon tetrachloride-treated rats by endothelin receptor antagonist TAK-044.
    Anselmi, K
    Subbotin, V
    Nemoto, E
    Gandhi, CR
    HEPATOLOGY, 2001, 34 (04) : 405A - 405A
  • [5] TAK-044: An endothelin receptor antagonist
    Watanabe, T
    Fujino, M
    CARDIOVASCULAR DRUG REVIEWS, 1996, 14 (01): : 36 - 46
  • [6] An endothelin receptor antagonist TAK-044 ameliorates carbon tetrachloride induced acute liver injury and portal hypertension in rats
    Gandhi, CR
    Nemoto, EM
    Watkins, SC
    Subbotin, VM
    LIVER, 1998, 18 (01): : 39 - 48
  • [7] Endothelin receptor antagonist TAK-044 arrests and reverses the development of carbon tefrachloride-induced cirrhosis in rats.
    Thirunavukkarasu, C
    Yang, YP
    Subbotin, VM
    Gandhi, CR
    HEPATOLOGY, 2003, 38 (04) : 338A - 339A
  • [8] Nonlinear pharmacokinetics of TAK-044, a new endothelin antagonist, in rats
    Takeuchi, T
    Tagawa, Y
    Hagihara, K
    Maeshiba, Y
    Yamashita, K
    Tsukuda, R
    Yoshimura, Y
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2001, 22 (06) : 221 - 230
  • [9] Disposition of TAK-044, a new endothelin antagonist, in rats and dogs
    Maeshiba, Y
    Takeuchi, T
    Kondo, T
    Yamashita, K
    Tsukuda, R
    Yoshimura, Y
    ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH, 2002, 52 (08): : 587 - 592
  • [10] Effects of a new endothelin receptor antagonist, TAK-044, on myocardial stunning in dogs
    Kitayoshi, T
    Ikeda, S
    Kubo, K
    AwaneIgata, Y
    Watanabe, T
    Fujino, M
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1996, 305 (1-3) : 137 - 143